Navigation Links
Vion Pharmaceuticals Engages Merriman Curhan Ford to Evaluate Strategic Alternatives
Date:10/12/2009

in(TM) be completed prior to regulatory approval. Triapine®, a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. For additional information on Vion and its product development programs, visit the Company's Internet web site at www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion being unsuccessful in achieving its strategic alternatives, including any combination of a restructuring of the Company and its debt, a sale of the Company or its assets, and raising new capital, in which case it may have to consider curtailing or ceasing operations or liquidating its assets, Vion's potential inability to obtain regulatory approval for its products, particularly Onrigin(TM) (laromustine) Injection, delays in the regulatory approval process, particularly for Onrigin(TM) (laromustine) Injection, delays or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies, clinical trials or interim clinical trial data are not confirmed by safety and efficacy results in later or final clinical trials, the need for additional research and testing, including the need for a new randomized trial of Onrigin(TM) prior to regulatory approval in accordance with the recommendation of the Oncologic Drug Advisory Committee, the inability to manufacture product, the potential inability to secure external sources of funding to continue operations, the inability to access capital and funding on favorable terms, continued operating losses and the inability to continue operations as a result, and a variety of other risks set forth from time to time in Vion's filings with the Securities and
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... DIEGO , March 4, 2015 Aethlon Medical, ... to address infectious diseases and cancer, today announced that ... scheduled to present a corporate overview at the 27th ... Ritz-Carlton Hotel in Laguna Niguel, California ... here ( http://www.roth.com/main/page.aspx?PageID=7207 ). A live webcast ...
(Date:3/4/2015)... 2015  Students from Indiana University School of Medicine ... are discovered. Through a partnership with Lilly ... IU School of Medicine are learning about drug development ... different and important roles in bringing new and innovative ... educator, scientific investigator, and health system administrator, I recognize ...
(Date:3/4/2015)... 2015  ECR Booth #317/Expo C - Varian Medical ... full spectrum of X-ray imaging solutions that bundle components ... enable greater patient throughput for manufacturers of mammography, fluoroscopy, ... are on display at the Annual European Congress of ... this week.   "This year,s exhibit ...
Breaking Medicine Technology:Aethlon Medical to Present at the 27th Annual ROTH Conference 2Lilly and IU School of Medicine Partner on Rotation Program for Medical Students 2Lilly and IU School of Medicine Partner on Rotation Program for Medical Students 3Varian Medical Systems to Showcase New X-Ray Imaging Components at the European Congress of Radiology (ECR) Annual Meeting 2Varian Medical Systems to Showcase New X-Ray Imaging Components at the European Congress of Radiology (ECR) Annual Meeting 3
... Strong, a health minister,for Hallelujah Acres, was only 52 when ... (normal is 4 or under). Although he,had no symptoms, a ... him to have a radical prostectomy to remove his,prostate and ... blocker Lupron for one year., The Lupron made him ...
... Bavarian Nordic, the,Danish-based biopharmaceutical company, has initiated a Phase ... multiantigen., Enrolment in a Phase I/II safety and ... has begun in the United,States. The first safety data ... will be available during first half of 2009., ...
Cached Medicine Technology:Prostate Cancer Treatment Offers Results Without Side Effects 2Prostate Cancer Treatment Offers Results Without Side Effects 3Bavarian Nordic Enters Clinical Trials with HIV Multiantigen Vaccine 2
(Date:3/4/2015)... Estates, CA (PRWEB) March 04, 2015 ... clever dialogue and lyrical music, will be performed by ... Rolling Hills Estates, CA, this March 6-22, 2015, on ... Arts Center at Peninsula High School (27118 Silver ... available one hour before the program or may be ...
(Date:3/4/2015)... March 04, 2015 The report ... client survey, marketing channels, industry development trend and ... the industry, including spices definitions, applications and industry ... market analysis are provided with a focus on ... market. A comparison between the international and Chinese ...
(Date:3/4/2015)... 04, 2015 Information Innovators Inc ... Dvorak has joined the company as Chief Technology ... technology focus for the company, including customer-centric strategies and ... 20 years of experience as a technology executive and ... roles at the FBI including oversight of enterprise data ...
(Date:3/4/2015)... BC (PRWEB) March 04, 2015 According ... , millions of people in the U.S. suffer from ... reflux. Medications are commonly prescribed to control acid production, ... surgical procedures can overly correct the problem and lead ... Market Opportunity, GERD occurs when the lower esophageal sphincter ...
(Date:3/4/2015)... Florida and Dayton, Ohio (PRWEB) March 04, 2015 ... nearly killed in an IED explosion in Iraq, tells ... while recovering. He received some free Chiropractic care from ... to Magnetic Resonance Therapy. , This is what Harris ... using the Magnesphere, I have clarity, I feel more ...
Breaking Medicine News(10 mins):Health News:The New Mel Brooks Musical Young Frankenstein Performance March 6-March 22, 2015, by the Award Winning Drama Department at Peninsula High School, Rolling Hills 2Health News:World Spices Market Overview & Development 2015-2020 Now Available at DeepResearchReports.com 2Health News:World Spices Market Overview & Development 2015-2020 Now Available at DeepResearchReports.com 3Health News:Information Innovators Inc. Announces Mr. John Dvorak as the New Chief Technology Officer 2Health News:Information Innovators Inc. Announces Mr. John Dvorak as the New Chief Technology Officer 3Health News:New and Proven Acid Reflux Treatments Offer Relief to Millions of Americans 2Health News:New and Proven Acid Reflux Treatments Offer Relief to Millions of Americans 3Health News:Decorated Veterans Endorse “Halos for Heroes” an Indiegogo campaign to Help Wounded Military Heal at Home 2Health News:Decorated Veterans Endorse “Halos for Heroes” an Indiegogo campaign to Help Wounded Military Heal at Home 3
... of Pharmaceutical Marketing Industry Due to New PhRMA ... 6 Pharmaceutical marketers are taking on the ... Systems, a unique marketing company whose integrated engagement ... the sector. In the past two years the ...
... A survey recently conducted by the Society of ... Compliance Association (HCCA) reveals that the declining economy may ... in business. In addition, this increased risk is ... risks are expected to at best hold steady, if ...
... /PRNewswire/ -- Akerman Senterfitt, one of the ... top 100 firms in the U.S., today announced that ... the auspices of the American Health Lawyers Association (AHLA) ... and issues concerning privilege and confidentiality. The live audiocast ...
... POINT, N.Y., Jan. 6 Akrimax Pharmaceuticals, LLC ... of pharmaceutical products for a global company beginning ... partners in a competitive process.Akrimax President Alan L. ... to acquire the Rouses Point facility which possesses ...
... KENILWORTH, N.J., Jan. 6 Schering-Plough Corporation (NYSE: ... results for the 2008 fourth quarter and full year on ... that day, Schering-Plough will conduct a conference call to review ... Fred Hassan, Schering-Plough,s chairman and CEO, and other members of ...
... for expanding role of patient flow automation PITTSBURGH, Jan. ... its clients, now more than 700 hospitals, solve their ... to increase capacity and improve patient flow is now ... have postponed building and expansion plans because of the ...
Cached Medicine News:Health News:Kyp Systems Takes on the Challenge of New Pharmaceutical Marketing Guidelines 2Health News:Kyp Systems Takes on the Challenge of New Pharmaceutical Marketing Guidelines 3Health News:Legal and Ethical Violations Risks Seen Rising, But Not Resources to Control the Risk 2Health News:Legal and Ethical Violations Risks Seen Rising, But Not Resources to Control the Risk 3Health News:Akerman Senterfitt Hosts National Panel Discussion on Patient Safety Organizations 2Health News:Akerman Senterfitt Hosts National Panel Discussion on Patient Safety Organizations 3Health News:Akrimax Pharmaceuticals Announces Manufacturing Partnership 2Health News:Schering-Plough Schedules Conference Call and Webcast for 2008 Fourth Quarter and Full Year Earnings 2Health News:TeleTracking Technologies to Focus on Growth 2Health News:TeleTracking Technologies to Focus on Growth 3
... four channel platelet aggregation profiler combined with ... conjunction with Microsoft WindowsTM, the PAP-4CD has ... automatic storage of test results, plus simplified ... modes are available: chromogenic assays, von willebrand ...
... 400 plus, innovation means 4 on-board ... cuvettes and im-proved operator ergonomics. This ... ease-of-use required for true workload consolidation, ... with only one analytical platform, one ...
... The Advia 2400 ... sample volume (as low ... water consumption (40 L/hour) ... The optional universal rack ...
Iron FS Ferene for determination of iron in serum. Available with Calibrator: Trucal U and Controls: Trulab N, Trulab P. For automated systems....
Medicine Products: